Response to "Estimating the cost of inappropriate antibiotic prophylaxis prior to dental procedures".

Infect Control Hosp Epidemiol

Division of Pediatric Infectious Diseases, Department of Infection Prevention and Control, and The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California.

Published: April 2024

Download full-text PDF

Source
http://dx.doi.org/10.1017/ice.2023.235DOI Listing

Publication Analysis

Top Keywords

response "estimating
4
"estimating cost
4
cost inappropriate
4
inappropriate antibiotic
4
antibiotic prophylaxis
4
prophylaxis prior
4
prior dental
4
dental procedures"
4
response
1
cost
1

Similar Publications

Introduction: This was the first phase 1 study conducted in the United States. It consisted of dose-escalation (part A) and multiple indication-specific cohort expansion (part B), investigating the safety and preliminary efficacy of toripalimab (anti-programmed cell death-1 inhibitor) in patients with advanced malignancies.

Methods: Patients with advanced malignancies that progressed after treatment with at least one prior line of standard systemic therapy, including the patients with advanced/recurrent cholangiocarcinoma (CCA), received toripalimab 240 mg every 3 weeks in part B.

View Article and Find Full Text PDF

Background: The persistently high mortality and morbidity rates of hepatocellular carcinoma (HCC) remain a global concern. Notably, the disruptions in mitochondrial cholesterol metabolism (MCM) play a pivotal role in the progression and development of HCC, underscoring the significance of this metabolic pathway in the disease's etiology. The purpose of this research was to investigate genes associated with MCM and develop a model for predicting the prognostic features of patients with HCC.

View Article and Find Full Text PDF

Background: Bladder urothelial carcinoma (BLCA) is globally recognized as a prevalent malignancy. Its treatment remains challenging due to the extensive morbidity, high mortality rates, and compromised quality of life from postoperative complications and the lack of specific molecular targets. Our aim was to establish a prognostic model to evaluate the prognostic significance, assess immunotherapy responses, and determine drug susceptibility in patients with BLCA.

View Article and Find Full Text PDF

Unravelling Eribulin's role in metastatic breast cancer: evaluating benefits for both triple negative and non-triple negative patients in real-world scenarios in resource-constrained settings.

Ecancermedicalscience

November 2024

Department of Palliative Medicine, Mahamana Pandit Madan Mohan Malaviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Varanasi 221005, India.

Background: Metastatic breast cancer (MBC) patients have numerous options for treatment. However, it is essential to consider treatments with favorable toxicity profiles and convenient modes of administration. Eribulin has shown effectiveness in aggressive MBC, but there is a lack of sufficient real-world data specific to Indian patients.

View Article and Find Full Text PDF

Burning and flaring of oil and gas following the 2010 Deepwater Horizon (DWH) oil spill generated high airborne concentrations of fine particulate matter (PM). Neurological effects of PM have been previously reported, but this relationship has received limited attention in the context of oil spills. We evaluated associations between burning-related PM and prevalence of self-reported neurological symptoms during, and 1-3 years after, the DWH disaster cleanup.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!